AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02498366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical tests
Description: each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3.
Study NCT01091298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)
Description: Single dose (0.5 mL) of the vaccine administered orally
Study NCT01091298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (0.5 mL) of the placebo administered orally
Study NCT00649935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets 600 mg
Description: 600mg, single dose fed
Study NCT00649935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® Tablets 600 mg
Description: 600mg, single dose fed
Study NCT02217644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 solution
Study NCT02217644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 low dose capsule
Study NCT00871533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- IFNα2b
Description: SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
Study NCT01874652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Weight Breast Implants
Description: Light Weight Breast Implants
Study NCT02217644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 high dose capsule
Study NCT00871533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- IFNα2b
Description: SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
Study NCT03285854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood, urine and stool samples
Description: Collection of blood, urine and stool samples, diet diary and bone scans
Study NCT02217644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03328767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early activity and Mobilisation intervention
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study NCT02927886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopy pyloromyotomy
Study NCT00891618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
Study NCT02156687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y mesh
Description: Y mesh
Study NCT02156687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual flat mesh
Description: Dual flat mesh
Study NCT03768856 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Temporally Feathered Radiation Therapy (TFRT)
Description: Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
Study NCT04637152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
Study NCT01971788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography of the infarct related artery
Study NCT01971788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography of the infarct related artery
Study NCT00588419 — intervention group
Intervention type: BEHAVIORAL
Intervention: breast exam and questionaire
Description: A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
Study NCT03326986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Study NCT00005086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00005086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00005086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00005086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT01720420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelReplace CC, NobelProcera Implant Bar
Description: Implants titanium with conical connection, individualized titanium bar
Study NCT02959476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Anesthetic
Study NCT02959476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive comparator
Study NCT02092883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: PK PET scan before and after ACTH treatment
Study NCT00588666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00588666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00538655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 400mg vs. 200mg (PO) daily
Study NCT03158831 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo-Controlled Graded Drug Challenge
Description: All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
Study NCT02107612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture
Study NCT02107612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denture
Study NCT02927886 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrapyloric injection of Botulinum toxin
Study NCT00187200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous VV Pacing
Description: Right ventricular and left ventricular pacing delivered simultaneously.
Study NCT00187200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequential VV Pacing
Description: Right ventricular and left ventricular pacing delivered sequentially.
Study NCT00588666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01337869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bascom Cleft Lift
Description: Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
Study NCT01337869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg Flap
Description: Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
Study NCT03829839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal administration, 24 international units (IU) oxytocin
Study NCT03829839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam 1 mg
Description: Oral administration of 1mg lorazepam
Study NCT02819336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days.
Study NCT02819336 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: 1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days.
Study NCT03450278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Description: Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
Study NCT02835768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based injury prevention program
Description: An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum.
Study NCT02385669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Checkpoint blockade inhibitor
Study NCT02385669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Study NCT03273348 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oncoplastic breast surgery
Description: , Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
Study NCT00601848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00601848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Study NCT00601848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00601848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00601848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Study NCT00601848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT02002819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Study NCT01129739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived MSCs
Description: 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
Study NCT01999413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEGAVEN
Description: AML Study treatment induction phase
Study NCT01999413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: AML Study treatment induction phase
Study NCT01999413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: AML Study treatment induction phase
Study NCT01545908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplant
Description: Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
Study NCT01545908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
Study NCT02787434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Screening Decision Aid
Description: All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
Study NCT02280928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
Study NCT02280928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
Study NCT02280928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-cognitive training
Description: The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
Study NCT03114982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of the Oka/SK strain of live, attenuated varicella virus
Study NCT03114982 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Preparation of the Oka/Merck strain of live, attenuated varicella virus
Study NCT03037658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering a financial incentive to increase walking
Description: After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time.
Study NCT05080179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Benefit/Social Norm
Description: As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!
Study NCT05080179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Benefit/No Social Norm
Description: As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app.
Study NCT05080179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Benefit/Social Norm
Description: As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!
Study NCT05080179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Benefit/No Social Norm
Description: As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app.
Study NCT02624401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous infusion
Study NCT02624401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous infusion
Study NCT02624401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Intravenous infusion
Study NCT02624401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalation
Study NCT02624401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline (Ringer's Acetate)
Study NCT03566693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM System
Description: continuous glucose monitor
Study NCT03566693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose meter
Description: Blue-tooth enabled blood glucose meter
Study NCT01552928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide 0.5 mg
Description: 0.5mg Anagrelide single oral dose
Study NCT01552928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide 2.5 mg
Description: 2.5mg Anagrelide single oral dose
Study NCT01552928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg Moxifloxacin single oral dose
Study NCT01552928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Anagrelide placebo + Moxifloxacin placebo single oral dose
Study NCT00654511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg, Intravenous (IV)
Study NCT03375255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-5051
Description: Single dose of SRP-5051 administered as an intravenous (IV) infusion.
Study NCT00075491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally
Study NCT00075491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00654511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2mcg/kg, Intravenous (IV)